2025
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
Herbst R, Cho B, Zhou C, Burotto M, Dols M, Sendur M, Moiseyenko V, Casarini I, Nishio M, Hui R, Pons-Tostivint E, Dudnik J, Ahmed S, Okpara C, Dutcus C, Yin L, Luo Y, Chirovsky D, Bhagwati N, Abreu D. Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. Journal Of Thoracic Oncology 2025, 20: 1302-1314. PMID: 40419140, DOI: 10.1016/j.jtho.2025.05.016.Peer-Reviewed Original ResearchNonsquamous non-small-cell lung cancerProgression-free survivalMetastatic nonsquamous non-small-cell lung cancerNonsquamous NSCLCNon-small-cell lung cancerFirst-line pembrolizumabOverall survivalTargetable genetic alterationsPlacebo armGenetic alterationsLung cancerTreatment-related adverse eventsFirst-line therapyMedian Follow-UpDouble-blind studyPrimary endpointPembrolizumabLenvatinibAdverse eventsChemotherapyFollow-upDisease progressionSafety signalsPemetrexedMonths
2023
Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
Merkin R, Chiang V, Goldberg S. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Therapeutic Advances In Medical Oncology 2023, 15: 17588359231175438. PMID: 37275964, PMCID: PMC10233588, DOI: 10.1177/17588359231175438.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsBrain metastasesTargetable genetic alterationsLocal therapyLung cancerStereotactic radiosurgeryDeath 1 ligand 1 expressionManagement of BMSole metastatic siteStage IV diseaseWhole brain radiotherapyLigand 1 expressionPD-L1 expressionProspective clinical trialsTime of diagnosisManagement of patientsCell lung cancerCancer-related deathGenetic alterationsCentral nervous systemGenetic driver alterationsAnaplastic lymphoma kinaseEpidermal growth factor receptorGrowth factor receptorUpfront radiotherapy
2022
Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma
Cadamuro M, Romanzi A, Guido M, Sarcognato S, Cillo U, Gringeri E, Zanus G, Strazzabosco M, Simioni P, Villa E, Fabris L. Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. Journal Of Personalized Medicine 2022, 12: 1086. PMID: 35887583, PMCID: PMC9324584, DOI: 10.3390/jpm12071086.Peer-Reviewed Original ResearchTumor-associated lymphangiogenesisTumor-draining lymph nodesTargetable genetic alterationsNovel therapeutic targetCholangiocarcinoma invasivenessLiver transplantationLiver resectionLymph nodesCurative potentialPrimary tumorAvailable treatmentsSurgical proceduresLymphatic metastasisTherapeutic targetTumor microenvironmentTranslational valueMolecular profilingGenetic alterationsLymphangiogenesisCholangiocarcinomaMetastasisProgressionCurrent knowledgeRecent findingsMolecular mechanisms
2016
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Schrader K, Cheng D, Joseph V, Prasad M, Walsh M, Zehir A, Ni A, Thomas T, Benayed R, Ashraf A, Lincoln A, Arcila M, Stadler Z, Solit D, Hyman D, Zhang L, Klimstra D, Ladanyi M, Offit K, Berger M, Robson M. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology 2016, 2: 1-8. PMID: 26556299, PMCID: PMC5477989, DOI: 10.1001/jamaoncol.2015.5208.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDNA Mutational AnalysisFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleMiddle AgedModels, GeneticNeoplasmsNew York CityPhenotypePrecision MedicinePredictive Value of TestsPrognosisRisk AssessmentRisk FactorsConceptsTumor-normal sequencingPathogenic germline variantsGermline variantsAdvanced cancer diagnosisClinical tumor sequencingCancer susceptibility genesTumor sequencingMemorial Sloan Kettering Cancer CenterStudies of targeted agentsIndividual cancer typesTumor genetic sequencingGermline findingsProportion of individualsTumor-specific variantsMendelian disease genesTargetable genetic alterationsCancer susceptibilityMatched normal DNACancer diagnosisTargeted tumor sequencingSingle-gene disordersCancer CenterMSK-IMPACTTumor profilingSomatic alterations
2014
Whole‐exome sequencing of pancreatic neoplasms with acinar differentiation
Jiao Y, Yonescu R, Offerhaus G, Klimstra D, Maitra A, Eshleman J, Herman J, Poh W, Pelosof L, Wolfgang C, Vogelstein B, Kinzler K, Hruban R, Papadopoulos N, Wood L. Whole‐exome sequencing of pancreatic neoplasms with acinar differentiation. The Journal Of Pathology 2014, 232: 428-435. PMID: 24293293, PMCID: PMC4048021, DOI: 10.1002/path.4310.Peer-Reviewed Original ResearchMeSH KeywordsAcinar CellsBiomarkers, TumorCarcinoma, Acinar CellCell DifferentiationChromosomes, HumanDNA Mutational AnalysisDNA, NeoplasmExomeFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedMutationPancreatic NeoplasmsPhenotypeConceptsFluorescence in situ hybridizationChromosomal levelPancreatic carcinomaAcinar differentiationSomatic mutationsGenetic alterationsWhole-exome sequencing analysisFamilial pancreatic ductal adenocarcinomaWhole-exome sequencingPancreatic neoplasmsSurgically resected pancreatic carcinomaIndividual base pairsResectable pancreatic carcinomaSequence analysisAcinar cell carcinomaTargetable genetic alterationsBase pairsPancreatic ductal adenocarcinomaConstitutional alterationsGenesCell carcinomaMutationsPoor prognosisDuctal adenocarcinomaPALB2
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply